12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)
Condition: Breast Cancer Interventions: Drug: Trastuzumab; Drug: Docetaxel Sponsor: Ruijin Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Docetaxel | HER2 | Herceptin | Hospitals | Research | Taxotere